In a recent Facebook Live webchat, Jacob Laubach, MD, MPP, Clinical Director of the Jerome Lipper Multiple Myeloma Center, discussed the different ways that patients can be treated with multiple myeloma, as well as exciting avenues of treatment, such as combination therapy.
Nurses at Dana-Farber are used to hearing patients gush about their children and grandchildren during chemotherapy treatments, but Stephanie Ann Benoit, RN, still smiles when recalling how Nancy Raisman sang the praises of her granddaughter. “Aly is going to be in the Olympics,” the lung cancer patient would say proudly, a prediction that came true … Read more
For endometrial cancer, as for virtually every form of cancer, advances in genomics are transforming the understanding and treatment of this disease, which arises in the lining of the uterus or womb. As part of the Profile research project at Dana-Farber, Brigham and Women’s Hospital, and Boston Children’s Hospital, investigators have scanned hundreds of endometrial … Read more
Perhaps more than any other childhood cancer, pediatric brain tumor treatment is incredibly complex and takes a team effort to care for a patient. Doctors and researchers are working to not only improve medicines and treatment methods, they are also striving to improve quality of life and long-term side effects for young patients. “The goal … Read more
Historically, brain tumors have been some of the most challenging types of cancers. A protective barrier around the brain—called the “blood-brain barrier”—can prevent cancer treatments from reaching the tumor. Recently, increased interest in immunotherapy has given new hope to getting through this barrier. “We know the immune system can get into the brain to fight … Read more
Over the last decade, treatment options for lung cancer patients have evolved drastically. Even in just the last few months, promising research has led to new, approved therapies, and researchers anticipate more advances are on the way. “Drugs are emerging at a rapid pace now,” says Geoffrey Oxnard, MD, of Dana-Farber’s Lowe Center for Thoracic … Read more
This post originally appeared on the AACR Cancer Research Catalyst Blog. This week, the American Association for Cancer Research (AACR) released the results of a national survey on American voters’ opinions about cancer and cancer research funding in conjunction with its fifth annual Cancer Progress Report. The report highlights how federally funded research can power … Read more
It looked like a scientific dead end – a clinical trial that found no benefit to a potential drug for a form of leukemia. But, like police detectives working a cold case, Dana-Farber scientists gathered hundreds of tissue samples that had been collected for the study – most of them languishing in laboratory cabinets, destined … Read more
Although malignant melanoma has been attracting much of the media spotlight because of promising new immunotherapy drugs, advances are also being made in other types of skin cancer. Nonmelanoma skin cancers, such as basal cell carcinoma and squamous cell carcinoma, are very common, with more than 3.5 million cases diagnosed annually. In fact, it’s estimated … Read more
In the treatment of blood cancers and disorders, doctors and researchers are focusing their sights on the immune system and how to bolster its ability to fight off diseases like leukemia, lymphoma and multiple myeloma. “Understanding how you control the immune system is a big theme in treatment for these diseases,” says David A. Williams, … Read more
In the 1940s, children diagnosed with leukemia had a grim prognosis; there was essentially nothing doctors could offer to treat the young patients, other than cortisone therapy to help with side effects of the disease. But in 1948, Dana-Farber founder Sidney Farber, MD, believed a drug that blocked folic acid would shut down the production of abnormal bone … Read more
Metastatic breast cancer (MBC), also known as stage IV breast cancer or advanced stage breast cancer, ultimately affects approximately 20-25 percent of all people with breast cancer. There is no cure for MBC, but new developments in treatment and research are helping patients live longer and experience a better quality of life. “There are women … Read more
Lung cancer, which causes more deaths worldwide than any other malignancy, is revealing its vulnerabilities under a sustained assault from science. Many of the most recent advances against the disease have a long pedigree at Dana-Farber. It was 10 years ago, in fact, that Dana-Farber scientists and elsewhere showed non-small cell lung cancers that carry … Read more
Although ovarian cancer is often difficult to treat, research continues to yield results that are improving outcomes and quality of life for many patients. “Ovarian cancer research and treatment is exciting today because there are so many resources available and we are no longer committed to just the standard chemotherapy,” says Susana Campos, MD, MPH, … Read more
“Science and Society” was the theme of this year’s American Society of Clinical Oncology (ASCO) 50th annual meeting. The meeting showcased cancer research from around the world. Some new findings from Dana-Farber researchers included: Joyce Liu, MD, MPH, of the Susan F. Smith Center for Women’s Cancers reported that, in a phase 2 clinical trial, … Read more
The fight against cancers of the digestive system – including colorectal, stomach, esophageal, hepatic, and pancreatic cancers – has made significant progress in the past 50 years, especially in prevention and early diagnosis of colorectal cancer, where screening with tests such as colonoscopies is continuing to make a major impact. “In some areas we have done … Read more
Every year, about 4,700 children in the United States are diagnosed with brain cancer – making it the most common solid tumor in children. It is also one of the most difficult cancers to treat. Brain tumors are the leading cause of cancer-related deaths in children under age 10 and the second leading cause of … Read more
Not long ago, a diagnosis of multiple myeloma — a cancer of the bone marrow — carried with it a very poor prognosis, with median survival estimates of just two to three years. Now, thanks in large part to research and treatment advances at Dana-Farber/Brigham and Women’s Cancer Center (DF/BWCC), this disease is for many … Read more
The 36th annual San Antonio Breast Cancer Symposium, which ran from Dec. 10-14, brought news of significant advances against a disease that strikes more than 230,000 women and 2,000 men in the United States each year. The more than 1,000 research papers presented by thousands of scientists and physicians ranged from laboratory explorations of the … Read more
Today, three quarters or more of all childhood cancer patients will be cured of their disease, a higher percentage than ever before. And the numbers will only get better as we learn more about the biology of childhood cancers and develop new ways of treating them.